Journal article

Thermoluminescence dosimetry for in-vivo verification of high dose rate brachytherapy for prostate cancer

R Das, W Toye, T Kron, S Williams, G Duchesne

AUSTRALASIAN PHYSICAL & ENGINEERING SCIENCES IN MEDICINE | SPRINGER | Published : 2007

Abstract

It was the aim of the study to verify dose delivered in urethra and rectum during High Dose Rate brachytherapy boost (HDRBB) of prostate cancer patients. During the first fraction of HDRBB measurement catheters were placed in the urethra and rectum of prostate cancer patients. These contained LiF:Mg,Ti Thermoluminescence Dosimetry (TLD) rods of 1 mm diameter, with up to 11 detectors positioned every 16 mm separated by radio-opaque markers. A Lorentzian peak function was used to fit the data. Measurements from 50 patients were evaluated and measured doses were compared with predictions from the treatment planning system (Plato Vs 13.5 to 14.1). Prospective urinary and rectal toxicity scores w..

View full abstract